Disruptive Psychopharmacology
Boris D. Heifets, Robert C. Malenka
JAMA Psychiatry June 26, 2019 DOI: 10.1001/jamapsychiatry.2019.1145 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Psychopharmacology Methamphetamine Hallucinogen Psychotherapist |
| Citations | 28 |
| Key points | MDMA and psilocybin have potential therapeutic utility, but their clinical use requires development of mental health care infrastructures. |
Abstract
This Viewpoint discusses the potential therapeutic utility of methylenedioxy-methamphetamine and psilocybin and outlines mental health care infrastructures that would need to be put in place should these drugs be approved for treatment.
Citations in the library
Cited by 15
- Reviewing the Potential of Psychedelics for the Treatment of PTSD The International Journal of Neuropsychopharmacology March 12, 2020
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Journal of Neuroscience November 30, 2020
- Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites Translational Psychiatry November 7, 2019
- Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments Expert Review of Clinical Pharmacology June 1, 2020
- Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy Frontiers in Neuroscience September 20, 2021
and 10 more in the library
Cites 4
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics May 1, 2019
- Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism American Journal of Psychiatry August 29, 2018
- Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor Elife October 25, 2018
- Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry April 5, 2016